Literature DB >> 1446053

Cytosol cathepsin-D content and proliferative activity of human breast cancer. The Comitato Italiano per il Controllo di Qualita del Laboratorio in Oncologia.

A Paradiso1, A Mangia, M Correale, I Abbate, G Ferri, A Piffanelli, L Catozzi, D Amadori, A Riccobon, M De Lena.   

Abstract

Mitogenic properties have been demonstrated in vitro for the lysosomal acidic protease cathepsin-D (cath-D). We investigated possible relationships between cath-D cytosol cell content and tumor proliferative activity in a series of 129 operable breast cancer patients. For total cytosol cath-D evaluation, a solid phase two-site immunoradiometric assay was utilized on tumor cell cytosol obtained for hormone receptor assay (DCC method). The percentage of S-phase cells was analyzed by 3H-thymidine autoradiographic assay. Median 3H-thymidine Labeling Index (3H-Tdr-LI) of the series was 2.7%; median cath-D content resulted 57 pmol/mg of protein cytosol and was significantly higher in node-positive with respect to the node-negative subgroup (p < 0.03). When classified in low, intermediate or high tumor cath-D content and slow or fast proliferative activity (cut-off: median values of the series), no significant agreement was found between the two variables. Statistical analysis, however, showed that a significant inverse correlation existed in node positive tumors between cath-D and 3H-Tdr-LI values which was even more evident in N-positive high estrogen receptor-positive (ER+) cases (coefficient of correlation = 0.6828; p = 0.0001). Cytosol cath-D content cannot be generally proposed as a direct marker of proliferative activity for operable breast cancer.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1446053     DOI: 10.1007/bf01831477

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  21 in total

1.  Increased secretion, altered processing, and glycosylation of pro-cathepsin D in human mammary cancer cells.

Authors:  F Capony; C Rougeot; P Montcourrier; V Cavailles; G Salazar; H Rochefort
Journal:  Cancer Res       Date:  1989-07-15       Impact factor: 12.701

2.  Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second E.O.R.T.C. Workshop, held on 16-17 March, 1979, in the Netherlands Cancer Institute.

Authors: 
Journal:  Eur J Cancer       Date:  1980-11       Impact factor: 9.162

3.  Proteinase and proteinase-inhibitor activities of rat uterine myometrium during pregnancy and involution.

Authors:  E G Afting; M L Becker; J S Elce
Journal:  Biochem J       Date:  1979-01-01       Impact factor: 3.857

4.  Cathepsin D assay in primary breast cancer and lymph nodes: relationship with c-myc, c-erb-B-2 and int-2 oncogene amplification and node invasiveness.

Authors:  J P Brouillet; C Theillet; T Maudelonde; A Defrenne; J Simony-Lafontaine; J Sertour; H Pujol; P Jeanteur; H Rochefort
Journal:  Eur J Cancer       Date:  1990-04       Impact factor: 9.162

5.  Feasibility and reproducibility of the [3H]-thymidine labelling index in breast cancer. The SICCAB Group for Quality Control of Cell Kinetic Determination.

Authors:  R Silvestrini
Journal:  Cell Prolif       Date:  1991-09       Impact factor: 6.831

6.  Tumor-proliferative activity, progesterone receptor status, estrogen receptor level, and clinical outcome of estrogen receptor-positive advanced breast cancer.

Authors:  A Paradiso; S Tommasi; A Mangia; V Lorusso; G Simone; M De Lena
Journal:  Cancer Res       Date:  1990-05-15       Impact factor: 12.701

7.  Immunoenzymatic assay of Mr 52,000 cathepsin D in 182 breast cancer cytosols: low correlation with other prognostic parameters.

Authors:  T Maudelonde; S Khalaf; M Garcia; G Freiss; J Duporte; M Benatia; H Rogier; F Paolucci; J Simony; H Pujol
Journal:  Cancer Res       Date:  1988-01-15       Impact factor: 12.701

8.  Tamoxifen treatment increases the concentration of 52K-cathepsin D and its precursor in breast cancer tissue.

Authors:  T Maudelonde; J Domergue; C Henquel; G Freiss; J P Brouillet; J Simony; H Pujol; H Rochefort
Journal:  Cancer       Date:  1989-04-01       Impact factor: 6.860

9.  Cell kinetics as a prognostic marker in node-negative breast cancer.

Authors:  R Silvestrini; M G Daidone; G Gasparini
Journal:  Cancer       Date:  1985-10-15       Impact factor: 6.860

10.  Characterization of laboratory working standard for quality control of immunometric and radiometric estrogen receptor assays. Clinical evaluation on breast cancer biopsies. Italian Committee for Hormone Receptor Assays Standardization.

Authors:  A Piffanelli; D Pelizzola; G Giovannini; L Catozzi; L Faggioli; M Giganti
Journal:  Tumori       Date:  1989-12-31
View more
  2 in total

1.  Quantitative immunohistochemical determination of cathepsin-D and its relation with other variables.

Authors:  S Veneroni; M G Daidone; G Di Fronzo; V Cappelletti; D Amadori; A Riccobon; A Paradiso; M Correale; R Silvestrini
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

2.  Stromal cell cathepsin D expression and long-term survival in breast cancer.

Authors:  H Joensuu; S Toikkanen; J Isola
Journal:  Br J Cancer       Date:  1995-01       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.